Browse by category

Anti-obesity medications, including semaglutide (Ozempic and Wegovy), can effectively help patients manage weight regained after...

The FDA has received adverse event reports after patients used compounded semaglutide for type 2 diabetes and weight loss. Drug...

Eli Lilly and Company has registered its intent to carry out a Phase 3b clinical trial that will see the company’s tirzepatide (Mounjaro)...

The UK’s regulatory body, NICE, has recommended the use of semaglutide (also called Wegovy or Ozempic) alongside a reduced-calorie diet...

Adults with overweight or obesity who took semaglutide demonstrated short- and longer-term improvements in controlling their eating...

Semaglutide is effective in helping adolescents lose weight and improves cardiac health, according to a study, ‘Once-Weekly Semaglutide...

It has been another busy month reporting the latest bariatric and metabolic, and obesity-related disease news. We hope we have brought...

The risk of type 2 diabetes mellitus (T2DM) is more than halved by weekly injections of new obesity drug semaglutide, according to...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Once-weekly subcutaneous semaglutide (2.4mg) is more effective on weight loss in conjunction with counselling and physical activity vs...